Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study

被引:14
作者
Winnette, Randall [1 ]
Martin, Susan [2 ]
Harris, Nimanee [3 ]
Deal, Linda S. [1 ]
机构
[1] Pfizer Inc, Patient Ctr Outcomes Assessment, New York, NY 10017 USA
[2] RTI Hlth Solut, Dept Patient Ctr Outcomes Assessment, Ann Arbor, MI USA
[3] RTI Hlth Solut, Dept Patient Ctr Outcomes Assessment, Res Triangle Pk, NC USA
关键词
Activity; Alopecia areata; Consequence; Development; Emotional; Hair loss; Impact; Patient-reported outcome; Qualitative; Symptom;
D O I
10.1007/s13555-021-00508-w
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Introduction Although alopecia areata (AA) profoundly impacts patients' physical appearance, emotional state, and daily activities, no treatment approved for AA currently exists. Patient-reported outcome (PRO) instruments currently used to capture patients' AA experiences do not meet the requirements to support claims of treatment benefit as described in the US Food and Drug Administration's 2009 PRO guidance. Our objective was to explore the consequences and priority treatment outcomes among individuals with AA and develop a PRO measure consistent with regulatory requirements that assesses these priorities and represents clinical benefit from the AA patient perspective. Methods Targeted literature and instrument reviews informed an initial concept set. Concept elicitation interviews with 20 adults with AA confirmed the relevance and importance of the initial concepts, identified additional relevant concepts, and informed an AA consequence model. Thematic analysis yielded a draft item pool, which was evaluated through two iterative rounds of cognitive debriefing interviews with 16 patients with AA (9 adults; 7 adolescents). Results Hair loss was the primary consequence of importance to patients with AA. Patients emphasized the need to differentiate hair loss by location: scalp, eyebrows, eyelashes, and body. Consequences of AA include difficulty conducting daily activities, particularly outdoor activities and exercise, and emotional impacts such as sadness, frustration, and negative self-image. Following cognitive debriefing interviews, 11 items were included to form the Alopecia Areata Patient Priority Outcome (AAPPO), assessing AA-related symptoms and impacts over the past week. Conclusions The AAPPO is a novel, content-valid PRO that captures the consequences of AA of the highest priority to patients.
引用
收藏
页码:599 / 613
页数:15
相关论文
共 17 条
[1]   Measurement properties of Skindex-16: A brief quality-of-life measure for patients with skin diseases [J].
Chren, MM ;
Lasek, RJ ;
Sahay, AP ;
Sands, LP .
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2001, 5 (02) :105-110
[2]   Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases [J].
Chren, MM ;
Lasek, RJ ;
Flocke, SA ;
Zyzanski, SJ .
ARCHIVES OF DERMATOLOGY, 1997, 133 (11) :1433-1440
[3]  
Coondoo Arijit, 2014, Indian Dermatol Online J, V5, P416, DOI 10.4103/2229-5178.142483
[4]   Development of a disease-specific instrument to measure quality of life in patients with alopecia areata [J].
Endo, Yuichiro ;
Miyachi, Yoshiki ;
Arakawa, Akiko .
EUROPEAN JOURNAL OF DERMATOLOGY, 2012, 22 (04) :531-536
[5]   Quality of life in alopecia areata: a disease-specific questionnaire [J].
Fabbrocini, G. ;
Panariello, L. ;
De Vita, V. ;
Vincenzi, C. ;
Lauro, C. ;
Nappo, D. ;
Ayala, F. ;
Tosti, A. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (03) :e276-e281
[6]   DERMATOLOGY LIFE QUALITY INDEX (DLQI) - A SIMPLE PRACTICAL MEASURE FOR ROUTINE CLINICAL USE [J].
FINLAY, AY ;
KHAN, GK .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1994, 19 (03) :210-216
[7]  
Food and Drug Administration, 2019, DRAFT GUID IND FOOD
[8]  
Food and Drug Administration, VOIC PAT SER REP US
[9]   Epidemiology and burden of alopecia areata: a systematic review [J].
Fricke, Alexandra C. Villasante ;
Miteva, Mariya .
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2015, 8 :397-403
[10]  
Mendoza Tito R, 2013, J Investig Dermatol Symp Proc, V16, pS51, DOI 10.1038/jidsymp.2013.19